- Home
- WF vs INCY Comparison
WF vs INCY Comparison
Compare WF & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WF
- INCY
- Stock Information
- Founded
- WF 1899
- INCY 1991
- Country
- WF South Korea
- INCY United States
- Employees
- WF N/A
- INCY N/A
- Industry
- WF Commercial Banks
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- WF Finance
- INCY Health Care
- Exchange
- WF Nasdaq
- INCY Nasdaq
- Market Cap
- WF 13.5B
- INCY 17.0B
- IPO Year
- WF N/A
- INCY 1993
- Fundamental
- Price
- WF $53.77
- INCY $105.22
- Analyst Decision
- WF
- INCY Buy
- Analyst Count
- WF 0
- INCY 19
- Target Price
- WF N/A
- INCY $89.19
- AVG Volume (30 Days)
- WF 50.5K
- INCY 2.8M
- Earning Date
- WF 10-29-2025
- INCY 10-28-2025
- Dividend Yield
- WF 3.96%
- INCY N/A
- EPS Growth
- WF 22.80
- INCY 3878.02
- EPS
- WF 3.03
- INCY 5.90
- Revenue
- WF $7,217,708,955.00
- INCY $4,813,105,000.00
- Revenue This Year
- WF N/A
- INCY $19.33
- Revenue Next Year
- WF $4.13
- INCY $10.47
- P/E Ratio
- WF $5.81
- INCY $17.95
- Revenue Growth
- WF 2.02
- INCY 18.09
- 52 Week Low
- WF $29.44
- INCY $53.56
- 52 Week High
- WF $57.97
- INCY $106.47
- Technical
- Relative Strength Index (RSI)
- WF 45.12
- INCY 79.03
- Support Level
- WF $54.26
- INCY $91.16
- Resistance Level
- WF $55.97
- INCY $106.47
- Average True Range (ATR)
- WF 0.96
- INCY 4.10
- MACD
- WF 0.09
- INCY 1.59
- Stochastic Oscillator
- WF 25.51
- INCY 94.41
About WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.